
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : HTL Biotechnology
Deal Size : $6.9 million
Deal Type : Financing
BIOPHTA Raises 6.5M Euros Funding to Transition its New Standard of Care for Eye Diseases
Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 03, 2024
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : HTL Biotechnology
Deal Size : $6.9 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : UI Investissement
Deal Size : $6.9 million
Deal Type : Financing
BIOPHTA Raises €6.5M For Eye Disease Therapy Clinical Transition
Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 03, 2024
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : UI Investissement
Deal Size : $6.9 million
Deal Type : Financing
